CALL/NOVO-NORDISK B/1450/0.1/16.01.26 | Real-time BOERSE MUENCHEN 19:26:16 17/05/2024 BST | ||
| 0.65 EUR | +1.56% |
|
| 1 month | +8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.65 | +1.56% |
| 16/05/24 | 0.64 | +4.92% |
| 15/05/24 | 0.61 | +3.39% |
| 14/05/24 | 0.59 | -4.84% |
| 13/05/24 | 0.62 | +17.20% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 07:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG5967 |
| ISIN | DE000GG59676 |
| Date issued | 14/03/2024 |
| Strike | 1,450 kr |
| Maturity | 16/01/2026 (607 Days) |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.69 € |
|---|---|
| Lowest since issue | 0.465 € |
| Spread | 0.05 € |
| Spread % | 7.58% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
